Trevena, Inc. - Common Stock (TRVN)
Frequently Asked Questions About Trevena, Inc. - Common Stock (TRVN)
Has Trevena, Inc. received any FDA approvals?
Yes, Trevena, Inc. has received approval from the U.S. Food and Drug Administration (FDA) for Olinvo, which is indicated for the management of moderate to severe acute pain in adults. This approval marks a significant milestone for the company and confirms the drug's safety and efficacy.
How can investors stay informed about Trevena's progress?
Investors can stay informed about Trevena's progress by following the company’s official website, subscribing to its press releases, and monitoring investor relations updates. Additionally, participating in earnings calls and attending industry conferences can provide insights into the company's strategy and performance.
How does Trevena ensure compliance with regulatory bodies?
Trevena is committed to maintaining high standards of compliance with regulatory bodies such as the FDA and EMA. The company has established comprehensive quality assurance processes, conducts rigorous clinical trials, and adheres to Good Manufacturing Practices (GMP) to ensure the safety and efficacy of its products.
Is Trevena involved in any partnerships?
Yes, Trevena actively seeks strategic partnerships with other biotechnology and pharmaceutical companies to enhance its research capabilities, share resources, and expand its market presence. These collaborations are essential for accelerating the development of its drug candidates.
What are Trevena's key therapeutic areas?
Trevena focuses on several key therapeutic areas, particularly pain management and neurological conditions, including anxiety and depression. The company aims to address unmet medical needs within these areas by developing innovative treatments that enhance patient outcomes.
What challenges does Trevena face in the biopharmaceutical market?
Trevena faces several challenges within the biopharmaceutical market, including competition from other companies, regulatory hurdles, and the need to demonstrate the clinical and commercial viability of its products. Navigating these challenges is crucial for the company's continued growth and success.
What does Trevena, Inc. do?
Trevena, Inc. is a biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) conditions. The company primarily engages in the discovery and commercialization of novel medications that aim to treat pain, sleep disorders, and other neurological conditions, leveraging its expertise in G-protein coupled receptors (GPCRs).
What impact does the opioid crisis have on Trevena's business?
The ongoing opioid crisis has heightened the demand for safer pain management alternatives, positioning Trevena's lead product candidate, Olinvo, as a potentially valuable solution. The company's focus on developing non-opioid pain therapies aligns with this urgent need, creating opportunities for market expansion.
What is the market outlook for Trevena, Inc.?
The market outlook for Trevena, Inc. is cautiously optimistic, driven by the company's innovative pipeline and the growing demand for effective CNS therapies. While challenges remain, Trevena's focus on addressing significant medical needs in pain management positions it favorably within the biopharmaceutical sector.
What is the significance of Trevena's technology platform?
Trevena's technology platform is pivotal in its drug discovery process, allowing the company to develop more selective and effective medications. This platform utilizes proprietary methodologies to design compounds that interact preferentially with GPCRs, enhancing therapeutic efficacy while reducing unwanted side effects.
What is the stock symbol for Trevena, Inc.?
The stock symbol for Trevena, Inc. is TRVN. The company’s shares are traded on the Nasdaq stock exchange, allowing for accessibility to investors interested in the biopharmaceutical sector.
What is Trevena's approach to drug development?
Trevena employs a unique approach to drug development by focusing on GPCRs, which are critical targets for various therapeutic applications. The company's strategy includes leveraging innovative chemistry and biology techniques to design drugs that achieve targeted effects with improved safety profiles.
What is Trevena's business strategy?
Trevena's business strategy focuses on advancing its innovative pipeline of drug candidates through clinical development to commercialization. The company aims to establish strategic partnerships with other pharmaceutical companies and leverage its proprietary technology to enhance its product offerings and market reach.
What is Trevena's lead product candidate?
Trevena's lead product candidate is Olinvo (formerly known as TRV130), an investigational intravenous medication for the treatment of moderate to severe acute pain. The drug is designed to provide analgesic efficacy while minimizing the side effects commonly associated with opioids.
What is Trevena's vision for the future?
Trevena's vision is to become a leader in the development of innovative treatments for CNS disorders, aiming to improve the quality of life for patients worldwide. The company is dedicated to advancing its pipeline and leveraging its technology platform to deliver safe, effective, and transformative therapies.
What recent developments has Trevena announced?
Recent developments at Trevena include announcements regarding the results of clinical trials for its drug candidates, updates on regulatory submissions, and potential partnerships aimed at bolstering its research initiatives. These developments are critical for driving the company's growth and advancing its portfolio.
When was Trevena, Inc. founded?
Trevena, Inc. was founded in 2007. Since then, the company has made significant strides in the research and development of new pharmaceutical products, particularly focusing on effective treatment modalities for various CNS conditions.
Where is Trevena, Inc. headquartered?
Trevena, Inc. is headquartered in Chesterbrook, Pennsylvania. The location facilitates collaboration with leading academic institutions and research centers to advance its drug development programs.
Who are the key members of Trevena's management team?
The management team at Trevena comprises experienced professionals with extensive backgrounds in biotechnology and pharmaceutical sectors. Notable members include the CEO and other executives who spearhead the company's strategic initiatives and oversee its research and development activities.
What is the current price of Trevena, Inc. - Common Stock?
The current price of Trevena, Inc. - Common Stock is 2.500
When was Trevena, Inc. - Common Stock last traded?
The last trade of Trevena, Inc. - Common Stock was at 4:00 pm EDT on October 7th, 2024
What is the market capitalization of Trevena, Inc. - Common Stock?
The market capitalization of Trevena, Inc. - Common Stock is 2.16M
How many shares of Trevena, Inc. - Common Stock are outstanding?
Trevena, Inc. - Common Stock has 863.79K shares outstanding.